Table 3 Baseline patient characteristics
GDT (n = 45) | Control (n = 45) | P Value | |
|---|---|---|---|
Male/female | 33% / 66% | 44% / 56% | 0.28 |
Age | 79 (74.5–83.5) | 79 (72.5–83) | 0.61 |
Body mass index | 24.8 (22.3–28.3) | 24.6 (21.4–26.8) | 0.44 |
ASA 1 | 0% | 0% | |
ASA 2 | 17 (38) | 10 (22) | 0.11 |
ASA 3 | 23 (51) | 28 (62) | 0.29 |
ASA 4 | 5 (11) | 7 (16) | 0.54 |
CAD | 5 (11) | 10 (22) | 0.16 |
Hypertension | 30 (67) | 24 (53) | 0.2 |
Liver disease | 0 | 1 (2) | 0.32 |
GFR > 90 ml | 4 (9) | 7 (16) | 0.33 |
GFR 60 - 90 ml | 11 (24) | 14 (31) | 0.48 |
GFR 30 - 60 ml | 28 (62) | 17 (38) | 0.02 |
GFR 15 - 30 ml | 2 (4) | 7 (16) | 0.08 |
Diabetes | 9 (20) | 9 (20) | 1.00 |
Beta receptor blocker | 14 (31) | 19 (42) | 0.27 |
Anticoagulation | 18 (40) | 18 (40) | 1.00 |
Acetylsalicyl acid | 9 (20) | 12 (27) | 0.46 |
ACE inhibitor | 13 (29) | 11 (24) | 0.63 |
ARBs | 8 (18) | 12 (27) | 0.31 |
Diuretics | 11 (24) | 15 (33) | 0.35 |
Nicotine dependence | 3 (7) | 5 (11) | 0.46 |
Indication for surgery: | |||
Trauma | 20 (44) | 19 (42) | 0.83 |
Arthrosis | 8 (36) | 8 (36) | 1.00 |
Infectious | 6 (13) | 7 (16) | 0.76 |
Necrosis | 3 (7) | 0 (0) | 0.08 |
Osteolysis | 0 (0) | 3 (7) | 0.08 |